Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013, Article ID 359683, 9 pages
Review Article

The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

1Pediatrics and Neonatology Unit, Imola Hospital, Via Montericco 4, 40026 Imola, Italy
2Neonatology, S. Orsola-Malpighi Hospital, Via Massarenti 11, 40138 Bologna, Italy

Received 8 March 2013; Revised 13 May 2013; Accepted 20 May 2013

Academic Editor: Roberto Burioni

Copyright © 2013 Marcello Lanari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Monoclonal antibodies are widely used both in infants and in adults for several indications. Humanized monoclonal antibodies (palivizumab) have been used for many years for the prevention of respiratory syncytial virus infection in pediatric populations (preterm infants, infants with chronic lung disease or congenital heart disease) at high risk of severe and potentially lethal course of the infection. This drug was reported to be safe, well tolerated and effective to decrease the hospitalization rate and mortality in these groups of infants by several clinical trials. In the present paper we report the development and the current use of monoclonal antibodies for prophylaxis against respiratory syncytial virus.